185750.KS KSC
Chong Kun Dang Pharmaceutical Corp.
1W: +0.5%
1M: -5.2%
3M: -3.7%
YTD: -30.2%
1Y: -21.2%
3Y: -6.3%
5Y: -40.3%
₩65,200.00 ($48.42)
+0.00 (+0.00%)
Weekly Expected Move ±2.3%
₩62184
₩63692
₩65200
₩66708
₩68216
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$67.4B
+4.8% ▲
5Y CAGR: -8.4%
Capital Expenditures
$140.8B
-113.1% ▼
5Y CAGR: +30.8%
Free Cash Flow
-$73.5B
-3952.7% ▼
Dividends Paid
$13.8B
-3.7% ▼
Buybacks
$1.8B
+88.9% ▲
Net Change in Cash
-$12.2B
-238.7% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $42.4B | $80.0B | $213.6B | $111.4B | $77.5B |
| Depreciation & Amort. | $27.5B | $33.6B | $37.0B | $39.8B | $44.7B |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$71.6B | -$77.3B | $29.7B | -$76.6B | -$67.5B |
| Other Non-Cash Items | $14.6B | $31.5B | $37.8B | -$10.3B | $12.7B |
| Operating Cash Flow | $12.9B | $67.7B | $318.2B | $64.3B | $67.4B |
| — Investing Activities — | |||||
| Capital Expenditures | -$51.8B | -$53.1B | -$68.8B | -$38.5B | -$179.1B |
| Acquisitions (Net) | -$3.4B | $142M | $0 | $0 | $555M |
| Investment Purchases | -$61.3B | -$57.2B | -$192.5B | -$430.8B | -$274.3B |
| Investment Sales | $21.9B | $44.4B | $89.5B | $500.1B | $207.5B |
| Other Investing | $3.8B | $348M | $491M | -$27.1B | $0 |
| Investing Cash Flow | -$90.8B | -$65.4B | -$171.3B | $3.7B | -$245.3B |
| — Financing Activities — | |||||
| Net Debt Issuance | $100.7B | -$263K | -$26.0B | -$30.5B | $185.9B |
| Stock Repurchased | -$1.9B | -$1.9B | -$6.0B | -$16.0B | -$1.8B |
| Dividends Paid | -$10.8B | -$11.2B | -$11.6B | -$13.3B | -$13.8B |
| Other Financing | -$2.8B | -$3.2B | -$17M | -$3.3B | -$3.3B |
| Financing Cash Flow | $85.1B | -$16.3B | -$43.7B | -$63.1B | $167.0B |
| Net Change in Cash | $8.2B | -$14.4B | $102.2B | $8.8B | -$12.2B |
| Cash End of Period | $131.8B | $117.4B | $219.6B | $228.5B | $216.2B |
| Free Cash Flow | -$38.9B | $14.7B | $249.4B | -$1.8B | -$73.5B |